The APPG on Prostate Cancer is supporting the APPG on Osteoporosis and Bone Health on a joint inquiry to examine how the NHS identifies, monitors and manages bone loss in patients at predictable high risk due to treatments and long-term conditions.

The inquiry will focus on primary fracture prevention, specifically where fracture risk is foreseeable but not consistently acted upon in practice. It will examine how bone health is addressed, or overlooked, within clinical pathways where fracture risk is well-evidenced.

On Thursday 2 July, the joint inquiry held it's first oral evidence hearing, focusing on prostate cancer, with the following witnesses providing evidence across two sessions.

Session 1 (chaired by Lord Black of Brentwood, co-Chair of the APPG on Osteoporosis and Bone Health)

• Lance Allen (Patient representative)

• Dr Helena Carreira (Assistant Professor, London School of Hygiene & Tropical Medicine)

• Kevin Mortimer (Patient representative)

Session 1 (chaired by Lord Mott, Officer of the APPG on Prostate Cancer)

• Dr Claire Higham (Consultant Endocrinologist, Christie Hospital)

• Dr Xue-Yan Jiang (Consultant Clinical Oncologist, Freeman Hospital's Northern Centre for Cancer Care)

• Ashwin Sachdeva (Consultant Urological Surgeon, The Christie Hospital)

The inquiry will be supplemented with a call for written evidence this summer, in addition to a lived experience survey, FOI requests to NHS bodies, and further evidence hearings with additional APPGs from autumn 2027.

Pictured above (L-R): Kevin Mortimer, Ashwin Sachdeva, Helena Carreira, Xue-Yan Jiang, Lord Taylor of Warwick, Lance Allen, Lord Mott)